Andrew Metry

A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales

Rachid Rafia, Marrissa Martyn‐St James, S Harnan et al. · Value in Health · 2022 · 24 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +14

Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

Philip Hykin, A Toby Prevost, Sobha Sivaprasad et al. · Health Technology Assessment · 2021 · 18 citations · Full text

Medicine, Ophthalmology, Pharmacotherapy +17

Modelling of hypothetical SARS-CoV-2 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness analysis

Matt Stevenson, Andrew Metry, Michael Messenger · Health Technology Assessment · 2021 · 14 citations · Full text

Pharmacy, Infectious Diseases, Pharmacoeconomics +17

Modelling of hypothetical SARS-CoV-2 point of care tests for routine testing in residential care homes: rapid cost-effectiveness analysis

Matt Stevenson, Andrew Metry, Michael Messenger · Health Technology Assessment · 2021 · 13 citations · Full text

Veterinary Medicine, Health Sciences, Infectious Diseases +11

Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

Becky Pennington, Abualbishr Alshreef, Laura Flight et al. · PharmacoEconomics · 2021 · 11 citations · Full text

Pharmacy, Ophthalmology, Pharmacoeconomics +15